

grant PE-2013-02357094 to Dr Toniolo, and The Juvenile Diabetes Research Foundation and Network for Pancreatic Organ Donors with Diabetes grant 25-2012-770 to Dr Toniolo. The study was conducted in collaboration with the Centro Linceo Beniamino Segre, Accademia dei Lincei, Rome, Italy.

Conflicts of interest: None disclosed.

Drs Broccolo and Drago contributed equally to this work.

Correspondence to: Francesco Broccolo, MD, BSc, Department of Medicine and Surgery, School of Medicine, University of Milano-Bicocca, Via Cadore 38, Monza 20052, Italy.

E-mail: francesco.broccolo@unimib.it

REFERENCES

1. Gao L, Zou G, Liao Q, et al. Spectrum of enterovirus serotypes causing uncomplicated hand, foot, and mouth disease and enteroviral diagnostic yield of different clinical samples. *Clin Infect Dis*; 2018. <https://doi.org/10.1093/cid/ciy341>. [e-pub ahead of print]. Accessed October, 2018.
2. Drago F, Ciccarese G, Gasparini G, et al. Contemporary infectious exanthems: an update. *Future Microbiol*. 2017;12:171-193.
3. Drago F, Ciccarese G, Broccolo F, Rebora A, Parodi A. Atypical hand, foot, and mouth disease in adults. *J Am Acad Dermatol*. 2017;77:e51-e56.
4. Baggen J, Jan Thibaut H, Strating JRP, van Kuppeveld FJM. The life cycle of non-polio enteroviruses and how to target it. *Nat Rev Microbiol*. 2018;16:368-381.
5. Staring J, van den Hengel LG, Raaben M, Blomen VA, Carette JE, Brummelkamp TR. KREMEN1 is a host entry receptor for a major group of enteroviruses. *Cell Host Microbe*. 2018;23:636-643.e5.

<https://doi.org/10.1016/j.jaad.2018.08.034>

Prognostic value of the Breslow:diameter ratio in cutaneous melanoma



To the Editor: The most frequently used staging system in melanoma is based on the TNM classification, which includes the variables for tumor thickness, lymphatic spreading, and the presence of distant metastasis and ulceration. The thickness of the primary tumor is assessed by the Breslow index, which influences the T stage; an increase in the Breslow index is directly associated with a decrease in overall survival and is the most decisive factor in this regard.^{1,2} The diameter of a melanoma is not always related to its increase in depth, which brings into question whether a proportion that takes into

Table I. General characteristics of the series

Characteristic	Value
Age, y, n = 306, n ± SD (range)	52.3 ± 15.6 (8-85)
Sex, n = 306	
Male	142 (46.4)
Female	164 (53.6)
Diagnosis, n = 306	
Superficial spreading melanoma	219 (71.6)
Nodular melanoma	68 (22.2)
Acral lentiginous melanoma	14 (4.6)
Lentigo maligna melanoma	5 (1.6)
Location, n = 306	
Head and neck	23 (7.5)
Lower limb	93 (30.4)
Trunk	150 (49.0)
Upper limb	40 (13.1)
Diameter, mm, n = 306, n ± SD (range)	12.8 ± 7.8 (6-60)
Breslow index, n = 306, n ± SD (range)	2.35 ± 2.40 (0.17-23.00)
BDR, n = 306, n ± SD (range)	0.21 ± 0.23 (0.01-2.99)
Clark level, n = 298	
II	56 (18.8)
III	130 (43.6)
IV	93 (31.2)
V	19 (6.4)
TNM stage, n = 306	
I	145 (47.4)
II	91 (29.7)
III	70 (22.9)
Ulceration, n = 265	75 (28.3)
Regression, n = 256	73 (24.6)
Inflammatory infiltrate, n = 256	
No	39 (15.2)
Mild	106 (41.4)
Moderate	79 (30.9)
Severe	32 (12.5)
Lymphovascular invasion, n = 191	39 (20.4)
Satellitosis, n = 53	4 (7.5)
Mitotic rate, n = 139	
<1	16 (11.5)
≥1	123 (88.5)
<2	57 (41.0)
≥2	82 (59.0)
Previous excision, n = 306	273 (89.2)
No. lymphatic drainages, n = 306	
1	240 (78.4)
2	62 (20.2)
≥3	4 (1.3)
Surgical technique, n = 306	
Margins + plasty	4 (1.3)
Exeresis + graft	70 (22.9)
Margins	226 (73.9)
SNB only	6 (2.0)

Continued

Table I. Cont'd

Characteristic	Value
Nodal involvement, n = 306	70 (22.9)
Type of nodal metastases, n = 303	
Isolated tumor cells	9 (13.6)
Micrometastases	25 (37.9)
Macrometastases	32 (48.5)
Treatment with interferon, n = 163	65 (39.9)
Radiotherapy, n = 257	14 (5.4)
Chemotherapy, n = 155	20 (13.2)

Values are n (%) except where indicated.

BDR, Breslow:diameter ratio; SD, standard deviation; SNB, sentinel node biopsy.

account these 2 variables could be more useful than the superficial dimension alone.³⁻⁵

A retrospective observational study was carried out to determine the relationship between the Breslow:diameter ratio (BDR) and overall survival or disease-free survival in patients with melanoma and to establish a cutoff for BDR that has prognostic value.

Patients who underwent surgery consecutively for cutaneous melanoma and a sentinel lymph node biopsy for diagnostic purposes were included. The cases with a minimum follow-up of 2 years were selected. The study was evaluated and approved by our institutional review board. Clinical and histopathologic variables from the primary tumor and the sentinel node were recorded. We recorded the follow-up variables, melanoma-specific overall survival, and melanoma-specific disease-free survival since the surgery in months. As an independent variable, BDR was calculated as the Breslow depth divided by the largest diameter of the lesion. Only complete lesions were considered, and depth and diameter were measured in millimeters after fixation for all the cases.

We determined potential cutoff points for the BDR variable through receiver operating characteristic curve analysis and the Youden test, and a survival analysis was performed, with the 2 groups of patients classified in accordance with their BDR. The survival analysis was performed by means of Kaplan-Meier curves and the log-rank test.

A total of 306 patients were included (Table I). The receiver operating characteristic curve for different values of BDR shows an area under the curve of 0.77 as a prognostic variable, with an optimal value of 0.15 (Youden index). Therefore, this value was considered when establishing into which groups the patients were classified.

The univariate analysis showed significant differences between BDR values >0.15 and ≤0.15





Fig 1. Melanoma-specific overall survival (A) and disease-free survival (B) of patients. The continuous line represents the group of patients with a Breslow:diameter ratio (BDR) of ≤0.15. The discontinuous line represents patients with a BDR of >0.15 ($P < .001$).

regarding age ($P = .003$), sex (men; $P = .013$), histologic type (nodular melanoma vs superficial spreading melanoma; $P = .001$), Clark level ($P < .001$), TNM stage ($P < .001$), ulceration ($P < .001$), lymphovascular permeation ($P < .001$), high mitotic index ($P < .001$), and lymph node involvement ($P < .001$). Among patients with lymph node disease, a BDR ≤0.15 was associated with isolated tumor cell metastasis or micrometastasis and a BDR >0.15 with macrometastasis ($P < .05$). Differences in melanoma-specific overall survival and melanoma-specific disease-free survival were found between these 2 BDR groups ($P < .001$) (Fig 1).

Considering these findings, BDR could be a useful complementary diagnostic tool in cutaneous melanoma assessment, and a cutoff point of 0.15

could be its prognostic limit. Further studies would be needed to assess if a diameter range should be applied to the BDR; although, in general, thin lesions of large diameters correlate with low BDR and thick lesions with a small diameters correlate with high BDRs, lesions with large diameters and focal deep components would suggest a favorable BDR and prognosis but an unfavorable Breslow prognosis.

Antonio Piñero-Madrona, MD, PhD,^a Alvaro Jesús Gómez-Ruiz, MD,^a Guadalupe Ruiz-Merino, BSc,^b Enrique Martínez-Barba, MD,^c Pablo Cerezuola-Fuentes, MD, PhD,^d José Neptuno Rodríguez-López, PhD,^e and Juan Cabezas-Herrera, PhD^e

From the Departments of Surgery,^a Statistics,^b Pathology,^c Oncology,^d and Molecular Research,^e Hospital Clínico Universitario “Virgen de la Arrixaca” and Universidad de Murcia, Murcia, Spain

Funding sources: Supported by grants from the Ministerio de Economía y Competitividad (co-financing with Fondos FEDER) (SAF2016-77241-R) and the Fundación Séneca, the Región de Murcia (19304/PI/14) to Drs Rodríguez-López, Cabezas-Herrera, and Piñero-Madrona.

Conflicts of interest: None disclosed.

Correspondence to: Antonio Piñero-Madrona, MD, PhD, Department of Surgery, Hospital Clínico Universitario “Virgen de la Arrixaca,” 30120 El Palmar, Murcia, Spain

E-mail: pineromadrona@gmail.com

REFERENCES

1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the Skin. In: Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK, Brookland RK, Brierley JD, Balch CM, Compton CC, Hess KR, Gershenwald JE, Jessup JM, Byrd DR, Winchester DP, Madera M, Asare EA, eds. *AJCC Cancer Staging Manual*. 8th Edition. Switzerland: Springer; 2017:563-585.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol*. 2009;27(36):6199-6206.
3. Moreno-Ramírez D, Ojeda-Vila T, Ríos-Martín JJ, Nieto-García A, Ferrándiz L. Association between tumor size and Breslow's thickness in malignant melanoma: a cross-sectional, multicenter study. *Melanoma Res*. 2015;25(5):450-452.
4. Crocetti E, Fancelli L, Caldarella A, Buzzoni C. Thickness and diameter in melanoma: is there a relation? *Tumori*. 2015; 102(1):e1-e3.
5. Voss B, Wilop S, Jonas S, et al. Tumor volume as a prognostic factor in resectable malignant melanoma. *Dermatology*. 2014; 228(1):66-70.

<https://doi.org/10.1016/j.jaad.2018.09.034>

Vulvar cancer association with groin hidradenitis suppurativa: A large, urban, midwestern US patient population study



To the Editor: Anogenital cancer risk factors include age, smoking, human papilloma virus, and lichen sclerosus. Recently, 13 cases of secondary anogenital cancer, including vulvar cancer, were described with pre-existing hidradenitis suppurativa (HS).¹ However, association between anogenital cancer and HS has not been assessed to date.

The aims of this study were to determine whether there is an association between HS and anogenital cancer and to compare the incidence of anogenital cancer among adult females with HS with that among the US adult female population.

Existing data from the Northwestern Medicine Enterprise Data Warehouse, a previously described repository of medical record data of more than 5 million patients,² were extracted; the data extracted were from January 2001 to October 2017 for females age 18 to 89 years with dermatologist follow-up of at least 1 year. In these data, HS was indicated by *International Classification of Diseases, Ninth and 10 Revision* (ICD-9/10) codes (705.83 and L73.2). The control population consisted of all adult female dermatology patients without HS. The outcomes of interest were a subsequent diagnosis of anal cancer (ICD-9/10 codes 154.2, 154.3, and C21) or subsequent diagnosis of genital cancer (cancer of the vulva, labia minora/majora, and vagina) (ICD-9/10 codes 184, C51, and C52) recorded at least 2 months after the diagnosis of HS (or first dermatology encounter date for the controls). The data collected included age, race, smoking status, a diagnosis of lichen sclerosus, and duration of follow-up.

Adjusted odds ratios and 95% confidence intervals were estimated by using multivariate logistic regression analysis. In addition, the Surveillance, Epidemiology, and End Results 2000-2014 database was utilized to estimate the nationwide incidence of anogenital cancer.³

Data for a total of 133,936 patients qualified for analysis (Table I and Fig 1). Of these patients, 716 had HS; vulvar cancer was diagnosed in 3 of the 716 (2 African American and 1 white patient age 45-59 years). No other anogenital cancers were detected in patients with HS. All 3 patients with vulvar cancer had groin HS (adjusted odds ratio, 5.56; 95% confidence interval, 1.74-17.76; $P = .004$), and none of the 3 had lichen sclerosus or human papilloma virus. Moreover, the age-adjusted incidence of vulvar cancer among females with HS in this study population (2.8 per 10,000 persons/y) was 8-fold greater than the age-adjusted nationwide